NCT03602820Active, not recruiting
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject. The study is a non-interventional, follow-up study of subjects who participated in previous AAV2-hRPE65v2 gene therapy clinical trials.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 41 (actual)
- First submitted
- 18 Jul 2018
- Start date
- 1 Jun 2015
- Primary completion date
- 31 Jan 2030
- Lead sponsor
- Genentech, Inc.
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT03602820
What you commit to
- Study type: Observational
- Participants enrolled: 41
- From 1 Jun 2015 to the primary completion date, 31 Jan 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Subjects who will not consent for study.
- Subjects who the investigators believe are not capable of performing study assessments
Who the study is looking for
- 1\. Subjects who participated in prior subretinal AAV2-hRPE65v2 gene therapy clinical studies
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.